{"id":679,"date":"2020-11-27T07:19:38","date_gmt":"2020-11-27T07:19:38","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=679"},"modified":"2020-11-27T07:19:38","modified_gmt":"2020-11-27T07:19:38","slug":"25-nov-2020-ace-i-arb-therapy-mortality-is-not-associated-with-ace-i-arb-therapy","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/25-nov-2020-ace-i-arb-therapy-mortality-is-not-associated-with-ace-i-arb-therapy\/","title":{"rendered":"(25 Nov 2020) ACE-I\/ARB therapy &#8211; mortality is not associated with ACE-I\/ARB therapy"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study<\/p>\n<p>https:\/\/doi.org\/10.1177\/1074248420976279<\/p>\n<p class=\"\">This multi-center, prospective study ( NCT4357535) enrolled patients hospitalized for COVID-19 and receiving one or more antihypertensive agents to manage either hypertension or cardiovascular disease. Of 338 enrolled patients, 245 (72.4%) were using ACE-I\/ARB on the day of hospital admission, and 197 continued ACE-I\/ARB therapy during hospitalization. Ninety-eight (29%) patients had a severe COVID-19, which was not significantly associated with the use of ACE-I\/ARB (OR 1.17, 95% CI 0.66-2.09; P = .57). Prehospitalization ACE-I\/ARB therapy was not associated with ICU admission, mechanical ventilation, or in-hospital death. Continuing ACE-I\/ARB therapy during hospitalization was associated with decreased mortality (OR 0.22, 95% CI 0.073-0.67; P = .008). ACE-I\/ARB use was not associated with developing the composite outcome of mechanical ventilation and in-hospital death (HR 0.95, 95% CI 0.51-1.78; P = .87) versus not using ACE-I\/ARB. Patients with hypertension or cardiovascular diseases receiving ACE-I\/ARB therapy are not at increased risk for severe COVID-19 on admission to the hospital. ICU admission, mechanical ventilation, and mortality are not associated with ACE-I\/ARB therapy. Maintaining ACE-I\/ARB therapy during hospitalization for COVID-19 lowers the likelihood of death.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study https:\/\/doi.org\/10.1177\/1074248420976279 This multi-center, prospective study ( NCT4357535) enrolled patients hospitalized for COVID-19 and receiving one or more antihypertensive agents to manage either hypertension&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/25-nov-2020-ace-i-arb-therapy-mortality-is-not-associated-with-ace-i-arb-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(25 Nov 2020) ACE-I\/ARB therapy &#8211; mortality is not associated with ACE-I\/ARB therapy&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[70,6,4],"tags":[75],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/679"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=679"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/679\/revisions"}],"predecessor-version":[{"id":680,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/679\/revisions\/680"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=679"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=679"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}